XML 67 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1
License and Collaboration Agreements - Additional Information (Detail)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 44 Months Ended
Nov. 30, 2020
USD ($)
Oct. 27, 2020
USD ($)
Jan. 31, 2024
USD ($)
Oct. 31, 2023
USD ($)
Apr. 30, 2023
USD ($)
Jan. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Apr. 30, 2022
USD ($)
Aug. 31, 2021
USD ($)
Jun. 30, 2024
USD ($)
License
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
License
Jun. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2024
USD ($)
License
Jan. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Development cost reimbursement received     $ 15,000,000                            
Revenue                   $ 199,685,000 $ 94,969,000 $ 372,009,000 $ 139,814,000        
Number of licensed products | License                   2   2     2    
EMPAVELI [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Revenue                   $ 24,512,000 22,303,000 $ 50,122,000 42,742,000        
SYFOVRE [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Revenue                   154,624,000 67,342,000 292,089,000 85,702,000        
Royalty revenue                       9,500,000          
Regulatory milestone payments     3,000,000 $ 2,000,000 $ 2,300,000                        
Royalty expense incurred                   18,400,000   18,400,000     $ 18,400,000    
Royalty Expense                       9,500,000          
Regulatory milestone incurred                           $ 5,000,000      
EMPAVELI and Aspaveli [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Royalty revenue                       3,100,000          
Milestone payments based on annual sales milestones     1,500,000                            
Royalty expense incurred                   11,100,000   11,100,000     11,100,000    
Royalty Expense                       3,100,000          
Swedish Orphan Biovitrum AB (Publ) [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Royalty Revenue                   4,400,000 2,400,000 $ 8,900,000 4,000,000        
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Upfront payment $ 250,000,000                                
Milestone payment received for achievement of regulatory development milestone               $ 50,000,000                  
Development cost reimbursement received           $ 65,000,000                      
Waived Payment     15,000,000                            
Royalties entitled to receive after first commercial sale of applicable licensed product period                       10 years          
Contract research and development reimbursement commitment   $ 80,000,000                              
Contract research and development expense                   0 $ 0 $ 0 $ 0   65,000,000    
Contract research and development current                           $ 15,000,000      
Remaining reimbursement payment     15,000,000                            
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] | Maximum [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events                                 $ 915,000,000
Development cost reimbursement                       80,000,000          
University of Pennsylvania [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Annual maintenance fees                       100,000          
Development milestone achievement             $ 5,000,000   $ 1,000,000                
University of Pennsylvania [Member] | EMPAVELI and Aspaveli [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Milestone payments based on annual sales milestones           $ 1,000,000                      
University of Pennsylvania [Member] | Maximum [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Aggregate milestones payments                   3,200,000   3,200,000     3,200,000    
Milestone payments based on annual sales milestones                       5,000,000          
2010 License Agreement [Member] | Maximum [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Aggregate milestones payments                   $ 1,700,000   1,700,000     $ 1,700,000    
Milestone payments based on annual sales milestones                       $ 2,500,000          
Sobi Agreement and Another Licensing Transaction [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Sublicense fee owed     $ 500,000                         $ 25,000,000